Methods and compositions for inhibiting diseases of the central nervous system
Methods and compositions for treating central nervous system diseases and disorders are disclosed.
1. An isolated composition comprising:
a) an immunogen, wherein said immunogen induces a humoral immune response against at least one abnormal protein of a central nervous system disease or disorder, and
b) at least one adjuvant that stimulates regulatory T cells,
wherein said immunogen consists of nitrated alpha synuclein or a fragment thereof,
wherein said nitrated alpha synuclein fragment is a carboxy terminal fragment consisting of the carboxy terminal 20 amino acids of alpha synuclein up to the carboxy terminal 70 amino acids of alpha synuclein.
2. The composition of claim 1 , further comprising at least one pharmaceutically acceptable carrier.
3. The composition of claim 1 , wherein said adjuvant is selected from the group consisting of vasoactive intestinal peptide, vitamin D, granulocyte macrophage colony stimulating factor, and transforming growth factor beta.
4. The composition of claim 1 , wherein said adjuvant is vasoactive intestinal peptide.
5. The composition of claim 1 , wherein said adjuvant is vasoactive intestinal peptide and said immunogen is nitrated alpha synuclein.
6. The composition of claim 1 , wherein said nitrated alpha synuclein is human nitrated alpha synuclein.
7. The composition of claim 1 , wherein said nitrated alpha synuclein comprises an amino acid sequence having at least 90% identity with SEQ ID NO: 13.
8. The composition of claim 1 , wherein said nitrated alpha synuclein fragment comprises at least 90% identity with amino acids 101-140 of SEQ ID NO: 13.
9. The composition of claim 1 , wherein said nitrated alpha synuclein or fragment thereof comprises at least one nitrotyrosine.
10. The composition of claim 3 , wherein said adjuvant is vasoactive intestinal peptide.
11. The composition of claim 3 , wherein said adjuvant is granulocyte macrophage colony stimulating factor.
12. A method for treating a central nervous system disease or disorder in a patient in need thereof, said method comprising administering an effective amount of the composition according to claim 1 to said patient, wherein said central nervous system disease or disorder is characterized by the presence of at least one abnormal protein and is selected from the group consisting of Parkinson's Disease, Alzheimer's Disease, amyotrophic lateral sclerosis, neuroAIDS, Crohn's Disease, and Huntington's Disease.
13. The method of claim 12 , wherein said adjuvant is selected from the group consisting of vasoactive intestinal peptide, vitamin D, granulocyte macrophages colony stimulating factor, and transforming growth factor beta.
14. The method of claim 13 , wherein said adjuvant is vasoactive intestinal peptide.
15. The method of claim 12 , wherein said central nervous disease or disorder is Parkinson's Disease and said immunogen is nitrated alpha synuclein.
16. The method of claim 12 , wherein said central nervous disease or disorder is Parkinson's Disease and said immunogen is a fragment of nitrated alpha synuclein.
17. The method of claim 12 , wherein said central nervous disease or disorder is Alzheimer's Disease and said immunogen is amyloid beta.
18. The method of claim 12 wherein said central nervous system disease or disorder is amyotrophic lateral sclerosis and said immunogen is superoxide dismutase.
19. The method of claim 12 , wherein said composition further comprises at least one pharmaceutically acceptable carrier.